BiondVax Pharmaceuticals Ltd. (NASD: BVXV), which released a shareholder letter at the end of the year to emphasize its accomplishments, has increased 14.86% to $3.40 in after-hours trading hours on the last check Friday.
What was revealed in the letter from BVXV?
Last Friday, BiondVax (BVXV) sent a letter from its CEO, Amir Reichman, outlining the company’s successes for 2022, positive preclinical trial findings for its inhaled COVID-19 NanoAb treatment, and recent funding initiatives to meet 2023 goals.
Due to a lack of a technical foundation to create relevant pharmaceutical goods, BiondVax conducted a thorough search with the assistance of consultants who are subject-matter experts in the field. In the course of the procedure, BVXV discovered a chance to collaborate with the Max Planck Institute for Multidisciplinary Sciences (MPI) and the University Medical Center Göttingen, Germany (UMG) on the creation of novel VHH nanosized antibodies (NanoAbs).
In order to develop a pipeline of “biobetter” NanoAbs—NanoAbs that interact with previously validated therapeutic targets and have a large and powerful chance of providing significant advantages over currently approved human monoclonal antibodies (mAbs) —BVXV signed exclusive agreements with MPI and UMG in late 2021 and early 2022.
In addition to the COVID-19 program signed in Q4 2021, BVXV finalized having signed a series of collaboration agreements with MPI and UMG in 2022 for the development of NanoAbs addressing diseases with significant unmet medical needs and promising commercial opportunities, such as psoriasis, asthma, macular degeneration, and psoriatic arthritis.
The Paul Ehrlich Institute (PEI) provided BVXV with helpful scientific guidance to carry out the first clinical studies in patients as a joint Phase 1/2a, evaluating both safety and efficacy, and reducing its new therapeutic deadlines. BVXV successfully transferred tech from MPI and started manufacturing the lead NanoAb candidate internally.
What goals has BVXV set for 2023?
By the end of 2023, BiondVax (BVXV) hopes to have completed the necessary processes to enter its inhaled COVID-19 NanoAb treatment into the first-in-human Phase 1/2a clinical study with financing in place. Studies on the toxicity and the NanoAb’s GMP manufacture are two of these processes. Additionally, BVXV plans to use its option to acquire an exclusive license to anti-IL-17 NanoAbs from its German partners at pre-negotiated financial terms, scale up internal NanoAb production, carry out an in a vitro proof-of-concept study, and possibly even conduct a preclinical trial of the IL-17 NanoAb as a treatment for psoriasis.